TDP-43 proteinopathy, genetic elimination of calcineurin results in accumulation of excess pTDP, exacerbated motor dysfunction, and accelerated neurodegenerative changes. In cultured human cells, treatment with FK506 (tacrolimus), a calcineurin inhibitor, results in accumulation of pTDP species. Lastly, calcineurin co-localizes with pTDP in degenerating areas of the central nervous system in subjects with FTLD-TDP and ALS. Taken together, these findings suggest calcineurin acts on pTDP as a phosphatase in neurons. 
Introduction
Neuronal cytoplasmic and nuclear aggregates of TAR DNA binding protein are the major pathological lesion in ~90 % of patients with amyotrophic lateral sclerosis (ALS) and ~50 % of patients with frontotemporal lobar degeneration (FTLD-TDP) [2, 46, 47] . Since the first report of TDP-43 positive aggregates in ALS and FTLD-TDP, other neurodegenerative diseases have been reported to have TDP-43 aggregates as a secondary pathologic feature in a subset of cases. These include Alzheimer's disease (AD), chronic traumatic encephalopathy, traumatic brain injury, progressive supranuclear palsy, corticobasal degeneration, argyrophilic grain disease, post-encephalitic parkinsonism, dementia with Lewy bodies, and Huntington's disease [1, 15, 19, 35, 40, 44, 52, 57, 61] . TDP-43 pathology has been correlated with severity of cognitive impairment and rate of cognitive decline in AD [23, 24, 59] . Further, numerous familial ALS causing mutations have been identified in TARDBP, the gene coding for TDP-43 protein, indicating that abnormal TDP-43 is not merely a hallmark of neurodegeneration, but that pathological TDP-43 drives disease [25, 31, 50, 56, 58] .
Pathological TDP-43 exhibits a variety of post-translational modifications not observed in healthy neurons, including ubiquitination, acetylation, SUMOylation, and phosphorylation [2, 10, 46, 53] . From these post-translational modifications, abnormal phosphorylation of TDP-43 is the most consistent and robust neuropathological marker of ALS/FTLD [45] . Specific sites of phosphorylation have been mapped and characterized in disease. These pathological phosphorylation sites cluster in the C-terminus of the TDP-43 protein, predominantly at serines 409 and 410 (S409/410), although phosphorylation at S379, S403, and S404 also correlate with disease pathology [18, 45] . Phosphorylation at S409/410 has been shown to promote decreased TDP-43 protein turnover, increased TDP-43 stabilization, cellular mislocalization of TDP-43, protein aggregation, and neurodegeneration [3, 7, 18, 32, 33, 62] .
Several kinases have been identified that phosphorylate TDP-43, including CK1/2, CDC7, and TTBK1/2 [18, 33, 34] . These kinases may act in response to overlapping or unique sets of cellular or environmental triggers. Phosphatases catalyze the reversal of protein phosphorylation on their protein targets by removing phosphate groups from modified tyrosine, serine, and threonine residues. However, in the case of TDP-43, the specific phosphatase(s) responsible for reversing pathological phosphorylation have yet to be identified. Here we show the phosphatase calcineurin binds and dephosphorylates TDP-43 at pathological sites S409/410. Calcineurin activity on TDP-43 prevents accumulation of toxic TDP-43 species preserving neuronal homeostasis.
Materials and methods

Yeast two-hybrid screen
Bait plasmids were constructed in the pLexA-N vector. Wild-type or M337V TDP-43 amino acids 260-414 were inserted under control of the LexA promoter. Cultures of TDP-43 bait plasmid yeast were grown overnight at 30 °C, brought to log phase the next day, and transformed with the Clontech Matchmaker Human Fetal Brain Library (1.3 mg/mL), a cDNA library in the pACT2 vector, resulting in 1.2 × 10 6 (Wild-type) or 8.2 × 10 6 (M337V) transformants. Transformants were plated on 150 mm plates of SD minimal media lacking leucine, tryptophan, and histidine and containing 25 mM 3-Amino-1,2,4-Triazole (3-AT) and grown at 30 °C. Colonies were picked and grown in SD broth lacking tryptophan and leucine. The candidate prey plasmid from the matchmaker library was isolated, transformed and amplified in E. coli, re-isolated, and identified by sequencing from primers within the pACT2 backbone.
Yeast spotting assay
L40 Ura
− yeast were grown overnight and brought to log phase in YPAD medium, then co-transformed with combinations of LexA TDP-43(WT), (A315T), and (M337V) with the pACT2/PPP3CC clone. pACT2/MS2 was cotransformed as a negative control for PPP3CC interaction. Transformants were plated on SD minimal media lacking leucine and tryptophan and grown at 30 °C. Colonies were isolated and grown in SD broth lacking tryptophan and leucine at 30 °C overnight. One OD 600 unit of yeast was collected, washed 3× in sterile water, diluted in series, then spotted on SD minimal media plates lacking leucine, tryptophan, and histidine with a titration series of 0, 5, 10, 15, 20, or 25 mM 3-AT. Images shown are at 10 mM 3-AT after 6 days of growth.
In vitro dephosphorylation assays
Purified recombinant human calcineurin and calmodulin were purchased from Enzo Lifesciences (Catalog #s BML-SE325, BML-SE163). Phosphorylated TDP-43 was prepared by in vitro phosphorylation using recombinant CDC7 kinase and glutathione-bound GST-TDP-43 fusion protein as previously described [33] . Dephosphorylation was carried out in dephosphorylation reaction buffer [50 mm HEPES, pH 7.2, 50 mM NaCl, 2 mM MnCl 2 , 1 mM CaCl 2 , 1 mM DTT]. In an 40 µl reaction volume, approximately 400 units of Calcineurin and 1 µg of calmodulin were added to 2 µg of phosphorylated bead bound TDP-43 protein and incubated at 30 °C for varying times up to 1 h.
3
C. elegans strains and transgenics
Construction and characterization of TDP-43 transgenic (tg) strains used were described previously [32] . In brief, TDP-43 tg strains were generated by introducing familial ALS mutant human TDP-43 cDNAs driven by the pan neuronal snb-1 promoter (Psnb-1::TDP-43) into the C. elegans genome. TDP-43 tg strains used were CK426: TDP-43(A315T), CK423: TDP-43(M337V), CK410: TDP-43(WT), and CK507: TDP-43(M337V SS/AA). tax-6(p657);TDP-43 tg and tax-6(ok2065);TDP-43 tg animals were obtained by crossing PR675 tax-6(p657) or RB1667 tax-6(ok2065) with CK426, CK410 and CK507. cnb-1(jh103);TDP-43 tg animals were obtained by crossing KJ300 cnb-1(jh103) with CK423, CK410, and CK507.
Behavioral analysis
Assessments of C. elegans locomotion were carried out as previously described with minor modifications [32] . In brief, 15-20 animals were placed at the center of a 100 mm plate of 5× concentrated peptone nematode growth media uniformly seeded with OP-50 bacteria. Animals were allowed to move freely for 30 min, and the radial distance traveled from the start point was recorded. Distance traveled was converted to micrometers per minute.
Neurodegeneration assays
Strains with GFP marked gamma-aminobutyric acid (GABA)-ergic motor neurons were generated by crossing tax-6(ok2065) with CK426, CK410, CK507, and the reporter strain EG1285 [Punc-47::GFP]. Animals were grown to day 1 adult. Living animals were immobilized on a 2 % agarose pad with 0.01 % sodium azide, and intact GABAergic neurons were scored under fluorescence microscopy on a DeltaVision Elite (GE, Issaquah, WA) imaging system using an Olympus 60× oil objective. Statistical significance was analyzed using Prism statistical software.
Cell culture
HEK 293 cells (from ATCC) were cultured under standard culture condition in Dulbecco's modified Eagle medium (DMEM), 10 % fetal bovine serum (FBS), penicillin (50 IU/ml)-streptomycin (50 mg/ml). For induced pTDP assays, cells were treated with FK506 (Prograf, Astellas Pharma) for 1.5 h before addition of 150 μM ethacrynic acid (EA) to induce production of phosphorylated TDP-43. Cells were harvested 3 h after addition of EA, washed in PBS, and snap frozen in liquid N 2 . For FK506 treatment alone, cells were incubated with the indicated concentrations of FK506 for 24 h, harvested, washed in PBS, and snap frozen in liquid N 2 . For Ni 2+ metal ion activation of calcineurin, cells were incubated with 500 μM NiCl 2 for 3 h, then harvested, washed in PBS, and snap frozen in liquid N 2 . For immunofluorescence assays, cells were grown on poly-d-lysine coated round cover slips (Neuvitro), treated with 10 μM FK506 for 1.5 h, followed by the addition of 150 μM EA for 3 h. Cells were fixed in fresh 2 % paraformaldehyde, followed by a 20 min incubation in citrate buffer (10 mM sodium citrate, 0.05 % Tween 20, pH 6.0) at 80 °C, and a 5 min incubation in 0.1 % Triton X-100. Cells were then incubated with the monoclonal antibody anti-phospho-TDP-43 (pS409/410) (CosmoBio TIP-PTD-M01) at 1:1000 dilution, with AlexaFluor 594 anti-mouse secondary antibody (Molecular Probes), followed by DAPI staining.
Immunoblotting
Samples were loaded and resolved on precast 4-15 % gradient SDS-PAGE gels and transferred to PVDF membrane as recommended by the manufacturer (Bio-Rad). On immunoblots, human TDP-43 was detected by anti-TDP-43 (Abcam ab57105). TDP-43 phosphorylated at S409/S410 was detected by a monoclonal antibody anti-phospho TDP-43 (pS409/410) (Cosmobio TIP-PTD-M01). C. elegans β-tubulin levels were measured using monoclonal antibody E7 (Developmental Studies Hybridoma Bank) as a loading control. Human calcineurin was detected using anticalcineurin antibody (Abcam ab82325). Dilutions were: 1:5000 for all primary antibodies. HRP labeled goat antimouse IgG was the secondary antibody (Jackson ImmunoResearch) and used at a dilution of 1:5000.
Protein extraction
Total protein fractions were obtained by lysing samples in RAB high salt buffer by homogenization as previously described [17] . For extraction of insoluble TDP-43 protein aggregates, fractions were obtained using methods previously described for analysis of FTLD-U and ALS brain samples [46] . Briefly, packed worm or cell pellets were resuspended in twice the amount (w/v) of Low Salt buffer (LS: [10 mM Tris, 5 mM EDTA, 10 % Sucrose, pH 7.5]). Samples were completely lysed by sonication and homogenates centrifuged at 25,000×g for 30 min. The supernatant constitutes the LS fraction. The pellet was re-extracted with non-ionic detergent containing buffer (TX: [10 mM Tris, 5 mM EDTA, 1 % Triton X-100, 10 % Sucrose, pH 7.5], centrifuged 20 min at 180,000×g, with the supernatant constituting the TX fraction. The resulting pellet was extracted with ionic detergent containing buffer (SARK: [10 and ALS (n = 2) cases were selected on the basis of having an autopsy-confirmed diagnosis of FTLD and FTLDrelated disorders or ALS. Control samples (n = 8) were from Center participants who were neurologically healthy, lacked pTDP or tau containing lesions, and were of a similar age. Neither cases nor controls showed neuropathologic changes of Lewy body accumulation, ischemic injury, or hemorrhage in consensus screening sections [20, 41] .
Immunohistochemistry and immunofluorescence analysis
Immunohistochemistry was performed on paraffin embedded frontal cortex and hippocampal sections from 10 FTLD-TDP cases and 8 normal control cases. Primary antibodies used were mouse monoclonal anti-Calcineurin A antibody CC-6 (Abcam, 1:500) and rat monoclonal anti-phospho TDP-43 409/410 (Antibody 1D3, gift of Manuela Neumann, 1:400). To minimize variability, sections from all cases (normal and affected subjects) were stained simultaneously for each antibody. Briefly, 5 μm sections were deparaffinized in xylene, rehydrated through graded alcohols, and an antigen retrieval step consisting of autoclaving sections in citrate buffer (1.8 mM citric acid/8.2 mM sodium citrate) was performed. Sections were treated for endogenous peroxidases with 3 % hydrogen peroxide, blocked in 5 % milk, incubated with primary antibody overnight at 4 °C, followed by biotinylated secondary antibody for 45 min at room temperature. Finally, sections were incubated in an avidin-biotin complex (Vector's Vectastain Elite ABC kit, Burlingame, CA) and the reaction product was visualized with 0.05 % diaminobenzidine (DAB)/0.01 % hydrogen peroxide in PBS. Nickel enhancement (DAB with 0.2 % Ni) was utilized for phospho TDP-43 visualization. For double labeling experiments, sections were simultaneously immunostained with anti-phospho TDP-43 and calcineurin, while secondary antibody application and detection was performed consecutively. For double-label immunofluorescence experiments on FTLD-TDP and ALS cases, AlexaFluor 488 goat antimouse and AlexaFluor 594 goat anti-rat secondary antibodies (Molecular Probes) were used and autofluorescence was quenched with 0.1 % Sudan Black. Primary antibodies were tested singly to confirm staining patterns and avoid misinterpretation of double label staining. Fluorescent secondary antibodies were validated for specificity using a spotted antibody assay (dot blot) and were confirmed to have no immunoreactivity on tissue in the absence of primary antibody. Colocalization plots for statistical analysis (Pearson's coefficient of correlation) were generated using softWoRX 5.0 software (Applied Precision, Issaquah, WA, USA). Colocalization analysis was performed on panel images taken using a 60× oil immersion objective.
Photomicrography and figure preparation
Immunohistochemistry photomicrographs were taken with a digital camera and imported into Adobe Photoshop for mounting. Fluorescent and immunofluorescent microscopy was performed on a Delta Vision microscope (Applied Precision, Issaquah, WA, USA) using a 20× air or a 60× oil immersion objective, a sCMOS camera, and 2 × 2 binning. Image acquisition, deconvolution, and analysis were performed using softWoRx 5.0 software (GE, Issaquah, WA). To optimize visualization of staining or immunofluorescence, photomicrographs were modified, when necessary, by adjusting brightness and contrast.
Results
Calcineurin binds and dephosphorylates the phosphorylated C-terminus of TDP-43
TDP-43 protein contains distinct functional domains, including two RNA recognition motifs, nuclear localization and export signals, and a prion-like G-rich C-terminal domain important for protein-protein interactions (Fig. 1a) . The C-terminus of TDP-43 is the site of the majority of ALS causing mutations identified in human disease, indicating this region of the protein may mediate pathological protein modifications and aggregation. Phosphorylation at the C-terminal serines 409 and 410 (S409/410) are a pathological signature of ALS, FTLD-TDP, and other TDP-43 proteinopathies.
To identify proteins that interact with the C-terminus of TDP-43, we performed a yeast two-hybrid screen using human TDP-43 amino acids 260-414 as bait (Fig. 1a) . We surveyed a human fetal brain library for TDP-43 C-terminus binding proteins. From this screen, we identified PPP3CC as a protein-protein interaction partner of both wild-type TDP-43 and familial ALS mutated TDP-43 (A315T, M337V) (Fig. 1b) . PPP3CC is the catalytic subunit of protein phosphatase 3 heterodimer, better known as calcineurin [43] . Calcineurin is a Ca 2+ /calmodulin-dependent protein phosphatase highly expressed in the mammalian brain [29] . Calcineurin has been extensively studied, and has numerous regulatory roles impacting synaptic plasticity, membrane receptors, ion channels, neuritogenesis, and response to ischemia [5, 6, 42] .
To test whether calcineurin can bind and dephosphorylate TDP-43 directly, we used an in vitro dephosphorylation assay incubating purified calcineurin with phosphorylated full-length wild type TDP-43. We observed that TDP-43 was robustly de-phosphorylated by calcineurin (Fig. 1c) , demonstrating a functional enzyme/substrate relationship between calcineurin and TDP-43 phosphorylated at S409/410 (pTDP).
Calcineurin regulates pTDP levels in vivo in C. elegans
Given calcineurin's observed activity on pTDP in vitro, it may regulate TDP-43 phosphorylation levels in vivo. To test this hypothesis, we utilized a C. elegans model of ALS that expresses full-length human TDP-43 pan-neuronally. This model exhibits progressive age-dependent movement defects and neurodegeneration, as well as accumulation of insoluble phosphorylated, ubiquitinated, and C-terminal truncated species of TDP-43 [32] . The C. elegans calcineurin A homolog TAX-6 plays important roles in behavioral modulation, but knockout of worm tax-6 is viable [30] . We crossed two different genetic loss-of-function alleles of tax-6 to our TDP-43 transgenic animals and assayed changes in TDP-43 phosphorylation by immunoblot. In the absence of functional tax-6, we saw an increase in the amount of total and phosphorylated human TDP-43 in transgenic animals expressing either WT or fALS mutant A315T TDP-43 ( Fig. 2a-e) , consistent with a conserved role for calcineurin as a TDP-43 phosphatase. We and others have observed a link between total TDP-43 and pTDP levels; when pTDP is increased, total TDP-43 protein also increases [7, 26, 33, 62] . This may be due to changes in protein stability or In both mammals and C. elegans, the absence of calcineurin's regulatory subunit results in greatly reduced catalytic activity [4, 54] . Therefore, we also tested the effect of a loss of function mutation in the calcineurin B regulatory subunit, cnb-1. We observed a similar increase in total TDP-43 and pTDP in both wild-type TDP-43(WT); cnb-1(-) and fALS mutant TDP-43(M337V); cnb-1(-) animals (Supplemental Fig. 1a-e) . Consequently, decreasing calcineurin activity by depletion of either catalytic or regulatory subunits allows pTDP accumulation, as a result of its failure to dephosphorylate TDP-43.
Detergent insoluble pTDP occurs in the neuronal inclusions of ALS and FTLD-TDP. Our C. elegans TDP-43 transgenic animals also accumulate detergent insoluble TDP-43 [32] . To determine whether tax-6(-) promotes accumulation of insoluble pTDP, we treated TDP-43(A315T); tax-6(-) animals with sequential protein extractions with detergents of increasing solubilizing strengths. We observed that both pTDP and total TDP-43 accumulate in the sarkosyl-insoluble fraction, and loss of functional tax-6 increases insoluble TDP-43 and pTDP (Fig. 2e) . We also assayed TDP-43(M337V); cnb-1(-) animals, and saw a similar accumulation of insoluble pTDP and total TDP-43 (Supplemental Fig. 1e) .
tax-6(-) animals move normally, while TDP-43 transgenic animals have obvious and progressive motor dysfunction leading to paralysis and death (Supplemental Fig. 1f, [32] ). However, in TDP-43(WT); tax-6(-) and TDP-43(A315T); tax-6(-) animals, we observed dramatic exacerbation of the TDP-43 induced motor dysfunction relative to TDP-43 animals alone (Fig. 2h, i) . cnb-1(-) animals are hyperactive relative to wild-type animals (Supplemental Fig. 1f) ; however, TDP-43(M337V); cnb-1(-) animals also displayed significantly worsened motor dysfunction (Supplemental Fig. 1g ). To test whether the tax-6(-) enhancement of TDP-43 phenotypes is due to phosphorylation at S409/410, we crossed tax-6(-) or cnb-1(-) with TDP-43 animals containing non-phosphorylatable serine to alanine substitutions at S409/410 (SS/AA) in addition to M337V. We found that loss of tax-6 increased levels of total TDP-43 ( Fig. 2f-g ). However, neither TDP-43(M337V SS/AA); tax-6(-) nor TDP-43(M337V SS/ AA); cnb-1(-) animals have any enhancement of locomotion dysfunction (Fig. 2j and Supplemental Fig. 1h ), indicating the synthetic toxicity of calcineurin loss-of-function and the TDP-43 transgene occurs through regulation of S409/410 phosphorylation and not through changes in levels of total TDP-43 protein.
Loss of calcineurin promotes TDP-43 mediated neurodegeneration in C. elegans
TDP-43 tg animals display degeneration of specific neuronal types with aging, including gamma-aminobutyric acid (GABA) positive inhibitory motor neurons [32] . Loss of calcineurin may promote neuronal dysfunction or increased neurodegeneration. C. elegans neuronal integrity can be assessed in vivo using a GABAergic D-type motor neuron reporter, Punc-47::GFP, which drives expression of GFP in all 19 D-type motor neurons [39] . To determine whether motor neurons are lost at a higher rate in TDP-43 tg; tax-6(-) animals, we scored intact GABAergic (Fig. 3a-f ). These animals also displayed dystrophic neurites, axonal defasciculation, and frank degeneration of axons (Supplemental Fig. 2 ). Therefore, in C. elegans the loss of calcineurin promotes neuronal dysfunction and death. To test whether phosphorylation at S409/410 is necessary for tax-6 loss of function mediated neurodegeneration, we tested TDP-43(M337V SS/AA); tax-6(-) animals. These animals had no appreciable neurodegeneration and were identical to control animals without TDP-43 transgenes (Fig. 3a) . Taken together, the biochemical, behavioral, and imaging data above demonstrate calcineurin functions in vivo to regulate TDP-43 phosphorylation levels and subsequent neurotoxicity.
T D P -4 3 ( A 3 1 5 T ) T D P -4 3 ( A 3 1 5 T ) ; t a x -6 ( o k 2 0 6 5 ) T D P -4 3 ( A 3 1 5 T ) T D P -4 3 ( A 3 1 5 T ) ; t a x -6 ( o k 2 0 6 5 )
SARK insoluble
Inhibition of calcineurin promotes accumulation of pTDP in human cells without altering TDP-43 RNA splicing functions
We have shown human calcineurin acts to directly dephosphorylate TDP-43 in vitro. Thus, calcineurin may normally prevent the accumulation of pTDP in vivo and inhibition of To test this hypothesis, we treated HEK293 cells with the calcineurin inhibitor FK506. FK506 binds the immunophilin FKBP12, forming a drug-immunophilin complex that interacts with and inhibits calcineurin activity [36] . Cells were incubated with FK506, followed by induction of full-length phosphorylated TDP-43 using a chemical trigger, ethacrynic acid [21] . We observed a dose-dependent increase in pTDP with calcineurin inhibition (Fig. 4a, b) . Interestingly, levels of total TDP-43 remain constant, perhaps due to the relatively rapid experimental time course. To determine whether FK506 treatment results in accumulation of detergent insoluble pTDP, we performed a sequential extraction using buffers with increasing solubilizing strengths [Low Salt < Triton x-100 < Sarkosyl < Urea]. We find that pTDP is present in all fractions including both soluble and sarkosyl-insoluble fractions (Fig. 4c) . Cell immunofluorescence following FK506 treatment and ethacrynic acid induction of pTDP shows increased pTDP staining compared to control cells (Fig. 4d-l) . This pTDP staining is distributed throughout the cytoplasm and nucleus, and includes areas of higher intensity staining that may represent pre-aggregates.
Cells incubated with FK506 in the absence of ethacrynic acid accumulated a lower molecular weight 35 kDa pTDP species (TDP-35) detectable by immunoblot (Supplemental Fig. 3a) . TDP-35 has been previously observed in human disease, and has been demonstrated to promote aggregation and recruit TDP-43 into inclusions [8, 9, 22] . To determine whether activation of calcineurin is protective, we treated HEK293 cells with the metal ion Ni
2+
. Ni 2+ is a robust calmodulin-independent activator of calcineurin in vitro and in vivo [28, 48, 51] . Incubating HEK293 cells with Ni 2+ treatment resulted in clearance of pTDP-35 (Supplementary Fig. 3b ), indicating that increased calcineurin activity can decrease pTDP species. Taken together, our data suggest calcineurin dephosphorylates TDP-43 in human cultured cells, and inhibition of calcineurin activity allows pTDP to accumulate under conditions of cellular stress.
Accumulation of pTDP may cause changes in gene expression or splicing profiles of TDP-43 regulated genes. We tested whether the expression of HDAC6, a TDP-43 regulatory target [27] , changed following FK506 treatment. However, we did not see any significant alteration of HDAC6 expression as measured by quantitative reverse transcription PCR (qRT-PCR) (Supplemental Fig. 3c) . We also evaluated splicing in TDP-43 target genes POLDIP3/ SKAR, STAG2, and FNIP1 [11, 14, 55] , but found no changes in their respective splicing profiles (Supplemental Fig. 3c) . Thus, pTDP accumulation observed following 
FK506 treatment does not appear to alter TDP-43 splicing functions for multiple known target genes.
Calcineurin co-localizes with pTDP-positive inclusions in FTLD-TDP and ALS
Calcineurin is a highly expressed neuronal phosphatase present in many regions of the brain, including the hippocampus and cerebral cortex [49] . To determine whether changes in calcineurin distribution pattern or localization were apparent in disease affected brain regions containing pTDP aggregates, we immunostained tissue from patients with FTLD-TDP and unaffected controls (normal, NL) ( Fig. 5 ; Table 1 ). We observed similar distributions of calcineurin in the hippocampus and frontal cortex in both FTLD-TDP and control tissue. In the hippocampus, calcineurin was abundant in the dentate granule cells as well as CA pyramidal neurons, while in the frontal cortex, calcineurin immunoreactivity was most prominent in cortical layers II, IV, and VI (Fig. 5) . FTLD-TDP cases and unaffected controls were qualitatively ranked for staining intensity in cortical layers II, IV, and VI (Table 2 ). In both cases and controls calcineurin staining was consistent in cortical layers II and VI. Interestingly, in cortical layer IV, calcineurin staining was mild (N = 3) or undetectable (N = 5) in all of the controls evaluated. However, calcineurin staining was detected in cortical layer IV in all FTLD-TDP cases evaluated. In FTLD-TDP cases, layer IV staining was ranked as moderate (N = 8) or robust (N = 1), with only one case ranked as mild. It is possible that increased calcineurin expression in FTLD-TDP cases is protective for neurons in cortical layer IV, as these neurons are typically spared pTDP pathology and neurodegeneration in FTLD-TDP. FTLD-TDP affected hippocampal and cerebral cortical regions rich in pTDP deposition were robustly immunoreactive for calcineurin (Fig. 6a-f) . To evaluate whether calcineurin is co-expressed in neurons with pTDP aggregates, we performed double-label immunohistochemistry for calcineurin and pTDP. We observed co-expression of calcineurin in cells bearing pTDP-positive lesions in hippocampal dentate granule cells, CA1 pyramidal cells, and frontal cortex layer II (Fig. 6g-i) . Motor neurons accumulate pTDP aggregates in ALS. To assess whether calcineurin is co-expressed with pTDP in disease affected spinal cord motor neurons, we performed double-label immunohistochemistry for calcineurin and pTDP. We found that 
calcineurin and pTDP staining also overlaps in these cells in cytoplasmic aggregates (Fig. 6j) . We did not observe calcineurin and pTDP co-localizaed in dystrophic neurites.
To confirm co-localization of calcineurin and pTDP, we performed double-label immunofluorescence for calcineurin and pTDP in FTLD-TDP hippocampal dentate granule cells (Fig. 7, Supplemental Fig. 4 ) and frontal cortex layer II (Fig. 8, Supplemental Fig. 5 ). We observed significant co-localization of calcineurin with pTDP-positive cytoplasmic aggregates in both brain regions in FTLD-TDP cases (Figs. 7d, e, 8d, e) . We also performed double-label immunofluorescence for calcineurin and pTDP on spinal cord sections from ALS patients ( Fig. 9 and Supplemental  Fig. 7 ). In these neurons, calcineurin and pTDP proteins are abundant and significantly co-localize. The co-occurrence of pTDP and calcineurin in neurons of degenerating regions is consistent with a role for calcineurin regulation of pTDP accumulation in ALS and FTLD-TDP. 
Discussion
We have demonstrated that the phosphatase calcineurin can directly interact with and dephosphorylate TDP-43. This is the first report of a phosphatase with specificity for pS409/410 TDP-43. Our data indicate regulation of TDP-43 phosphorylation is critical to maintaining neuronal function and viability. We have shown purified recombinant human calcineurin catalyzes dephosphorylation of purified human pTDP in vitro. In a C. elegans model of TDP-43 proteinopathy, genetic loss of calcineurin function dramatically worsens motor phenotypes, pTDP accumulation, and neurodegeneration. In mammalian cell culture, pharmacological inhibition of calcineurin drives accumulation of phosphorylated TDP-43, indicating calcineurin has a conserved role in regulating pTDP. In disease affected brain regions from patients with FTLD-TDP, we observe overlap and co-localization of calcineurin protein and pTDP-positive lesions in both the frontal cortex and hippocampus. We observe a similar co-localization of calcineurin and pTDP TDP-43 phosphorylation may be a regulated cellular event balanced by the activities of specific kinases and phosphatases. While pTDP is not detected in normal human brain, it is possible that it is transiently produced at low levels and rapidly de-phosphorylated. We do observe a low level of 35 kDa pTDP in HEK293 cells under normal culture conditions (Supplementary Fig. 3b) . pTDP may influence aspects of TDP-43 protein metabolism or function, possibly in response to specific or general cellular stresses. While the endogenous or environmental triggers of neuronal TDP-43 phosphorylation remain unclear, in mammalian cell culture full-length pTDP is induced under conditions of oxidative stress [21, 26] . If cellular homeostasis is disrupted, an imbalance between phosphate addition and removal on TDP-43 could lead to accumulation of pTDP and subsequent neurotoxicity (Fig. 10) . This hypothesis is consistent with our data showing Ni 2+ mediated activation of calcineurin decreases endogenous pTDP-35 present in HEK293 cells (Supplementary Fig. 3b) .
Our hypothesis is supported by another neuropathological observation: while calcineurin staining intensity appeared consistent between FTLD-TDP cases and controls in cortical layers II and VI, staining in cortical layer IV was stronger in patients than in controls. Layer IV is typically spared TDP-43 pathology and neuronal loss in FTLD-TDP. It is possible that upregulation of calcineurin in these neurons protects against the accumulation of pTDP. 10 Calcineurin protects against the accumulation of neurotoxic pTDP. a Under normal cellular conditions, low levels of pTDP are generated and rapidly cleared through the action of the phosphatase calcineurin. b During an acute cellular stress or following dysregulation or inhibition of calcineurin, the balance between non-phosphorylated and phosphorylated TDP-43 is shifted towards production of pTDP, leading to neuronal dysfunction and eventual cell death This study demonstrates normal calcineurin activity antagonizes the activity of TDP-43 kinases. Taken together our data have potential clinically relevant implications. Calcineurin inhibitors have clinical utility as immunosuppressant drugs to prevent transplanted organ rejection [38] . Clearly calcineurin inhibition on its own does not trigger ALS or other TDP-43 proteinopathies in treated patients. However, lymphocytes from patients with ALS have decreased calcineurin activity levels compared to controls [13] , perhaps indicating changes in calcineurin activity are playing a role in the genesis or progression of disease. A subset of patients who have received calcineurin inhibitors following organ transplant have adverse neurological and psychological effects, including tremor, neuralgia, peripheral neuropathy, psychosis, hallucinations, seizures, cerebellar ataxia, motor weakness, or reversible encephalopathy [60] . In some cases, neurotoxic symptoms persist after discontinuation of calcineurin inhibitors [12] . Suppressing calcineurin activity may unmask latent TDP-43 proteinopathy or exacerbate progression of TDP-43 pathology in TDP-43 proteinopathy patients. The relationship between calcineurin inhibitor use and TDP-43 proteinopathy warrants further study. Calcineurin inhibitors have been proposed as a therapeutic strategy for ALS on the basis of immunosuppressive/anti-neuroinflammatory mechanisms, and a clinical trial using FK506 in ALS has been initiated [16] . Our data demonstrate that calcineurin inhibition can trigger pTDP accumulation in some contexts, and suggest caution should be taken in these approaches to therapy.
